Spacer
Spacer
Spacer
 
Best of the Best: Today's Top Investment Ideas
Get ready for Dr. Reddy's (RDY) Print E-mail Digg It!
Thursday, 11 June 2009

 "India-based Dr. Reddy’s Laboratories (NYSE: RDY), a generic-drugs play with solid market positions in India, Russia, the US and Germany," says Asian stock expert Yiannis Mostrous.

In his specialty newsletter, The Silk Road Investor, he explains why he has chosen the firm as his latest "Stock of the month".

"Seventy percent of the firm’s growth comes from generic drugs, and the trend there has been favorable.

"New products, market share gains and a revamp of the supply chain in India should contribute to profitability. The company is also building a proprietary pipeline to supplement it core business. 

"Management is implementing tighter cost controls. The company is capable of annual revenue growth above 10%, which would enable earnings growth of around 20% per year.

"Margins should stay elevated at around 15 to 20; the outside range is attainable given that margins were around 16% last year.

"It seems that the worst for the company’s business has passed. Dr. Reddy’s could reach the USD $3 billion revenue mark in a couple years, up from current revenue of USD $1.6 billion.

"Dr. Reddy’s expects most of the growth to come from global generics, especially from the US. According to management, US growth will be driven by a near doubling of its prescription market share (2.1% in 2008), which would make it a top-five generics company.

"It plans to launch exclusive products in the next three years and to double its portfolio from the current 50 to 100 new drug applications.

"In India the supply chain will be overhauled to improve availability, while new product introductions will be accelerated in order to improve the company’s portfolio.

"Russia should remain highly profitable; management is focused on improving market share in Moscow and St. Petersburg, and expanding hospital coverage and the over-the-counter segment.

"Over the long term an aging global population, pressures to contain costs in developed economies, and new markets (e.g., Japan) will drive the company’s performance. Buy Dr. Reddy’s Laboratories."




Spacer
 
Search Our Archives
Trading and Investing Tips
Ebix (EBIX): A stock split buy

 In his 2-for 1 advisory, Neil Macneale focuses exclusively on buying stocks that have just announced upcoming stock splits. The latest buy in his portfolio is Ebix (NASDAQ: EBIX).

Read more...

ETF expert targets energy

 "One sector I’ve been watching closely for an attractive entry point is energy, and that point is here in the Energy Select Sector SPDR (NYSE: XLE)," says Doug Fabian in The ETF Trader.

Read more...

Revlon (REV): A beauty buy

 "Revlon (NYSE: REV) promises a better look for both consumers and investors," says Ian Wyatt. In his The SmallCap Investor, he says, "The company is firing on all cylinders." 

Read more...

A 'Select' pick in technology

 "I remain bullish on technology heading into 2010," says fund expert Jim Lowell. In The Fidelity Investor, he reviews one of his long-standing buys in the sector -- Select Technology (FSPTX).

Read more...

CVS (CVS): A Ben Graham value

 In The Cabot Benjamin Graham Value Letter, an exceptional service that picks stocks meeting the criteria of the legendary investor, J. Royden Ward looks at CVS Caremark (NYSE: CVS).

Read more...

Royale Energy (ROYL): Gas gains

 Konrad Kuhn, a specialist in low-priced stocks, sees upside potential in Royale Energy (NASDAQ: ROYL), a speculative play on natural gas. Here's the latest from The Kon-Lin Letter.

Read more...

Bernie bets: Puts and calls

 Bernie Schaeffer uses a combination of fundamental and technical and sentiment indicators to select his stock and options trades. Here's a long and a short idea from The Options Advisor.

Read more...

Disney (DIS): High quality value

 "An improving economy provides lots of leverage for theme-park, media, and movie operations at Walt Disney (NYSE: DIS)," says Chuck Carlson in his The DRIP Investor.

Read more...

The US dollar: A contrary view

 "Everybody thinks the US dollar is toast but I suspect that a sharp, if temporary rally will be with us before long," says Carl Delfeld in his Chartwell ETF Advisor. Here's his overview.

Read more...

Adens stick with gold

 "Despite recent gains gold is not yet overbought and the current rise is likely headed higher," say resource experts Mary Anne and Pamela Aden. Here's their latest from The Aden Forecast.

Read more...

Spacer
Support TheStockAdvisors.com



FeedTheBull - Top Stock market and Finance Sites
newsflashr network
 
Get A Quote
Symbol
Most Popular Articles
Translate This Site


 

Enter email:

 

 Our Partners

 Newsletter Newsmore...
Delfeld: Red, White & Bold

Global expert Carl Delfeld's new book -- Red, White & Bold -- is now available. Steve Forbes says, "Carl's perspective is truly unique and insightful in  understanding the global economy."


Toby Smith goes "green"

Toby Smith, editor of ChangeWave Investing, has just published his new book on investing in green technology -- Billion Dollar Green.


Gone Fishin' Portfolio

A new book from The Oxford Club's Alexander Green -- The Gone Fishin' Portfolio -- provides an all-weather approach to building long-term wealth.


An expert's guide to China

Check out Jim Trippon's new book, Becoming Your Own China Stock Guru. To order the book, click here.


©2008 The Stock Advisors | About TSA | Home | News From The Newsletters | Ask The Experts | Disclaimer
Clicky Web Analytics